WAVE Life Sciences (NASDAQ:WVE) Trading 6.3% Higher - Here's Why
WAVE Life Sciences (NASDAQ:WVE) shares rose 6.3% to $8.61, with 1.11 million shares traded. Analysts have set various price targets, with Cantor Fitzgerald at $10, Citigroup at $16, and Oppenheimer at $24. The stock has a consensus rating of "Moderate Buy" and an average target price of $20.36. The company reported a quarterly EPS of ($0.31), missing estimates, and had revenue of $8.70 million. Institutional investors own 89.73% of the stock, with significant recent activity from hedge funds.
WAVE Life Sciences Ltd. (NASDAQ:WVE - Get Free Report) traded up 6.3% on Friday . The stock traded as high as $8.66 and last traded at $8.61. 1,110,407 shares changed hands during trading, a decline of 14% from the average session volume of 1,293,867 shares. The stock had previously closed at $8.10.
Get WAVE Life Sciences alerts:
Analysts Set New Price Targets
- Wave Life Sciences Rockets 70% on Historic RNA Editing Success
Several research firms have commented on WVE. Cantor Fitzgerald began coverage on WAVE Life Sciences in a report on Tuesday, April 29th. They issued an "overweight" rating and a $10.00 price target for the company. Citigroup began coverage on WAVE Life Sciences in a research note on Wednesday, July 16th. They issued a "buy" rating and a $16.00 price target on the stock. Oppenheimer began coverage on WAVE Life Sciences in a report on Monday. They issued an "outperform" rating and a $24.00 price objective for the company. Wells Fargo & Company cut their price objective on shares of WAVE Life Sciences from $24.00 to $21.00 and set an "overweight" rating for the company in a research report on Thursday. Finally, Raymond James Financial initiated coverage on shares of WAVE Life Sciences in a research report on Wednesday, June 11th. They issued an "outperform" rating and a $14.00 price target for the company. One investment analyst has rated the stock with a sell rating, one has given a hold rating and thirteen have given a buy rating to the company's stock. According to MarketBeat, WAVE Life Sciences currently has a consensus rating of "Moderate Buy" and an average target price of $20.36.
Get Our Latest Report on WVE
WAVE Life Sciences Trading Up 6.5%
- Sarepta Therapeutics Inc.: Why it's a rising gene therapy star
The stock's 50-day moving average price is $7.12 and its two-hundred day moving average price is $8.35. The stock has a market capitalization of $1.34 billion, a P/E ratio of -9.59 and a beta of -1.01.
WAVE Life Sciences (NASDAQ:WVE - Get Free Report) last announced its quarterly earnings results on Wednesday, July 30th. The company reported ($0.31) EPS for the quarter, missing the consensus estimate of ($0.29) by ($0.02). The business had revenue of $8.70 million for the quarter, compared to analysts' expectations of $11.52 million. On average, equities research analysts predict that WAVE Life Sciences Ltd. will post -1.14 earnings per share for the current year.
Insider Activity at WAVE Life Sciences
In other news, Director Gregory L. Verdine sold 30,000 shares of the company's stock in a transaction dated Friday, June 13th. The shares were sold at an average price of $6.95, for a total transaction of $208,500.00. Following the completion of the transaction, the director directly owned 282,517 shares of the company's stock, valued at approximately $1,963,493.15. This represents a 9.60% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Company insiders own 23.98% of the company's stock.
Institutional Investors Weigh In On WAVE Life Sciences
Hedge funds have recently bought and sold shares of the business. Adage Capital Partners GP L.L.C. lifted its position in WAVE Life Sciences by 30.1% during the first quarter. Adage Capital Partners GP L.L.C. now owns 12,516,500 shares of the company's stock valued at $101,133,000 after purchasing an additional 2,894,396 shares during the period. Price T Rowe Associates Inc. MD boosted its position in shares of WAVE Life Sciences by 63.1% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 5,098,866 shares of the company's stock worth $63,074,000 after acquiring an additional 1,972,262 shares during the last quarter. Polar Capital Holdings Plc bought a new position in shares of WAVE Life Sciences during the fourth quarter worth $12,370,000. MPM Bioimpact LLC lifted its position in WAVE Life Sciences by 138.5% during the fourth quarter. MPM Bioimpact LLC now owns 1,489,237 shares of the company's stock valued at $18,422,000 after purchasing an additional 864,766 shares during the last quarter. Finally, Driehaus Capital Management LLC lifted its position in WAVE Life Sciences by 14.6% during the fourth quarter. Driehaus Capital Management LLC now owns 6,712,449 shares of the company's stock valued at $83,033,000 after purchasing an additional 853,589 shares during the last quarter. Institutional investors own 89.73% of the company's stock.
WAVE Life Sciences Company Profile
(Get Free Report)Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company's RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders.
Further Reading
- Five stocks we like better than WAVE Life Sciences
- What Investors Need to Know to Beat the Market
- Play It Cool: Why Comfort Systems USA Is a Hidden AI Winner
- Transportation Stocks Investing
- Rocket Lab Reports Next Week: Here’s What Investors Should Know
- Growth Stocks: What They Are, What They Are Not
- Apple Stock: Big Earnings, Small Move—Time to Buy?
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Should You Invest $1,000 in WAVE Life Sciences Right Now?
Before you consider WAVE Life Sciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and WAVE Life Sciences wasn't on the list.
While WAVE Life Sciences currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
